Bluebird reveals positive gene therapy data
The therapy targets cerebral adrenoleukodystrophy (CALD), the most severe manifestation of adrenoleukodystrophy (ALD), a rare metabolic disorder.
Read More
Tag: Lenti-D
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
